Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02703779 |
|
Recruitment Status :
Completed
First Posted : March 9, 2016
Results First Posted : June 18, 2021
Last Update Posted : June 18, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Multiple Myeloma | Drug: Bortezomib Drug: Granulocyte colony-stimulating factor (G-CSF) Drug: Mozobil | Phase 2 |
High dose chemotherapy with autologous stem cell transplant has resulted in improved overall survival and is currently considered an effective first line therapy applicable to the majority of patients with multiple myeloma. However disease relapse is inevitable and remains the primary cause of mortality in this cohort.
The purpose of this study is to estimate the proportion of subjects with plasma cell contamination of harvested stem cell product in standard and treatment arms. The study will explore whether or not in-vivo purging of malignant tumor plasma cells will improve progression free survival (PFS) for patients.
The study will consist of two groups:
Group A: Standard of Care (SOC) stem cell collection without in-vivo purging with bortezomib. Granulocyte colony-stimulating factor (G-CSF) and Mozobil used if needed.
Group B: Bortezomib 1.3mg/m^2 will be given subcutaneously (SQ) on days -11 and -8 followed by Granulocyte colony-stimulating factor (G-CSF) on days -4 through -1 prior to stem cell harvest (day 0).
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 101 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Exploratory Trial to Estimate the Proportion of Patients With Tumor Cell Contaminated, Flow Positive Leukapheresis Products Collected With and Without Bortezomib as In-vivo Purging Prior to Autologous Stem Cell Harvest for Multiple Myeloma |
| Actual Study Start Date : | March 2016 |
| Actual Primary Completion Date : | October 4, 2019 |
| Actual Study Completion Date : | April 8, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Stem cell collection without in-vivo purging with Bortezomib
Standard of Care Stem cell collection without in-vivo purging with Bortezomib. Standard of Care drugs Granulocyte colony-stimulating factor (G-CSF) +/- Mozobil (the latter if needed). NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B |
Drug: Granulocyte colony-stimulating factor (G-CSF)
Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.
Other Names:
Drug: Mozobil Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
Other Name: plerixafor |
|
Experimental: Stem cell collection with in-vivo purging with Bortezomib
Bortezomib will be given subcutaneously (SQ) at 1.3 mg/m2 on day -11 and day -8 followed by Granulocyte colony-stimulating factor (G-CSF) given SQ on day -4 thru day -1 and continued until the collection is completed. Mozobil will be given if needed. There must be at least 72 hours between each dose of bortezomib. NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B |
Drug: Bortezomib
Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.
Other Name: VELCADE Drug: Granulocyte colony-stimulating factor (G-CSF) Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.
Other Names:
Drug: Mozobil Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
Other Name: plerixafor |
- Multiparametric Flow Cytometry - Minimum Residual Disease [ Time Frame: Day 0 for all subjects (Day 0 is the day of stem cell collection) ]Estimate the proportion of subjects with plasma cell contamination (defined as >0.01% and at least 100 cellular events) of harvested stem cell product by multi parametric flow cytometry (MFC) from patients with myeloma undergoing autologous stem cell collection 1) by standard of care mobilization using Granulocyte colony-stimulating factor (G-CSF) with or without Mozobil and 2) after two doses of bortezomib as in vivo purging plus standard of care using G-CSF with or without Mozobil.
- Multiparametric Flow Cytometry - Cluster of Differentiation 34 (CD34)Assessment [ Time Frame: Within the first 30 days after stem cell collection ]Estimate the proportion of subjects who have a successful collection of stem cells (> 2 million Cluster of Differentiation 34 (CD34) cells/Kg of body weight) for autologous transplant in both treatment groups.
- Cluster of Differentiation 34 (CD34) Enumeration [ Time Frame: Within the first 30 days after stem cell collection ]Estimate the percentage of Cluster of Differentiation 34 (CD34) positive cells in circulating peripheral blood as a measure of mobilization on the days of collection.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects must meet all of the inclusion criteria to participate in this study.
- Ability to understand, and the willingness to sign a written Informed Consent Form
- Diagnosis of multiple myeloma undergoing planned autologous stem cell transplantation
- Age ≥ 18 years
- Karnofsky Performance Status (KPS) 70 or above, Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2
-
Adequate organ and marrow function as defined below:
- leukocytes ≥ 3,000/micro Liter (mcL)
- absolute neutrophil count ≥ 1,500/mcL
- platelets ≥ 100,000/mcL
- total bilirubin within normal institutional limits NOTE: For this study, subjects with bilirubin levels > 1.5 Upper Limit of Normal (ULN) are excluded from enrollment in this study.
- Aspartate Aminotransferase (AST) ( Serum Glutamic Oxaloacetic Transaminase [SGOT]) ≤ 2.5 X institutional upper limit of normal
- Alanine Aminotransferase (ALT) (Serum Pyruvic Glutamic Transaminase [SPGT]) ≤ 2.5 X institutional upper limit of normal
- creatinine within normal institutional limits
- Women of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days following completion of therapy. Should a woman or partner become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician and the investigator immediately.
-
A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
Exclusion Criteria:
- Subjects meeting any of the exclusion criteria at baseline will be excluded from study participation.
- Current or anticipated use of other investigational agents. NOTE the following clarification for this study: Prohibited Concurrent Therapy:
Participation in clinical trials with other investigational agents that are not included in this trial, within 14 days of the start of this trial until 2 weeks after participant has received the last dose of bortezomib for mobilization.
- Hypersensitivity to bortezomib, boron or mannitol or Granulocyte colony-stimulating factor (G-CSF)
- Subject has received > 6 months of lenalidomide (Revlimid®) therapy prior to stem cell collection
- Subject has known brain metastases. Presence of brain metastases should be excluded from this clinical trial because of poor prognosis and because patients often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
- Grade 3 or higher peripheral neuropathy
- Bilirubin levels > 1.5 ULN
-
Uncontrolled inter-current illness including, but not limited to
- ongoing or active infection
- symptomatic congestive heart failure
- unstable angina pectoris
- cardiac arrhythmia
- psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant or nursing: There is a potential for congenital abnormalities and for this regimen to harm nursing infants.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02703779
| United States, Kansas | |
| The University of Kansas Medical Center | |
| Westwood, Kansas, United States, 66205 | |
| Principal Investigator: | Siddhartha Ganguly, MD | The University of Kansas - Cancer Center |
Documents provided by Siddhartha Ganguly, University of Kansas Medical Center:
| Responsible Party: | Siddhartha Ganguly, Medical Doctor, University of Kansas Medical Center |
| ClinicalTrials.gov Identifier: | NCT02703779 |
| Other Study ID Numbers: |
2015-IIT-BMT-MM-AutoSCT |
| First Posted: | March 9, 2016 Key Record Dates |
| Results First Posted: | June 18, 2021 |
| Last Update Posted: | June 18, 2021 |
| Last Verified: | May 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
|
Multiple Myeloma Bortezomib Autologous Stem Cell Purging In-vivo purging |
Ex-vivo purging Leukapheresis Contaminated Stem Cell Harvest Stem Cell Transplant Transplantation |
|
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders |
Immune System Diseases Plerixafor Bortezomib Lenograstim Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |